Brief: Angion Biomedica Corp - First Patient Enrolled In Phase 2 Trial Of ANG-3070 In Primary Proteinuric Kidney Diseases

Elicio Therapeutics

04/01/2022 21:19

Jan 4 (Reuters) - Angion Biomedica Corp  ANGN.O :
    * ANGION BIOMEDICA CORP - FIRST PATIENT ENROLLED IN PHASE 2
TRIAL
OF ANG-3070 IN PRIMARY PROTEINURIC KIDNEY DISEASES
    * ANGION BIOMEDICA CORP - WILL END 2021 WITH ABOUT $88.8
MILLION
IN CASH AND CASH EQUIVALENTS
    * ANGION BIOMEDICA - EXPECTS TO FILE AN IND AT END OF 2022
FOR A
GLOBAL PHASE 2 TRIAL OF ANG-3070 IN PATIENTS WITH IDIOPATHIC
PULMONARY FIBROSIS

Source text for Eikon:  ID:nGNX8wKNLF 
Further company coverage:  ANGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))